Show simple item record

dc.contributor.authorPrezioso, Carla
dc.contributor.authorMoens, Ugo
dc.contributor.authorOliveto, Giuseppe
dc.contributor.authorBrazzini, Gabriele
dc.contributor.authorPiacentini, Francesca
dc.contributor.authorFrasca, Federica
dc.contributor.authorViscido, Agnese
dc.contributor.authorScordio, Mirko
dc.contributor.authorGuerrizio, Giuliana
dc.contributor.authorRodio, Donatella Maria
dc.contributor.authorPierangeli, Alessandra
dc.contributor.authord'Ettorre, Gabriella
dc.contributor.authorTurriziani, Ombretta
dc.contributor.authorAntonelli, Guido
dc.contributor.authorScagnolari, Carolina
dc.contributor.authorPietropaolo, Valeria
dc.date.accessioned2021-07-05T09:26:28Z
dc.date.available2021-07-05T09:26:28Z
dc.date.issued2021-06-09
dc.description.abstractSevere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a global pandemic. Our goal was to determine whether co-infections with respiratory polyomaviruses, such as Karolinska Institutet polyomavirus (KIPyV) and Washington University polyomavirus (WUPyV) occur in SARS-CoV-2 infected patients. Oropharyngeal swabs from 150 individuals, 112 symptomatic COVID-19 patients and 38 healthcare workers not infected by SARS-CoV-2, were collected from March 2020 through May 2020 and tested for KIPyV and WUPyV DNA presence. Of the 112 SARS-CoV-2 positive patients, 27 (24.1%) were co-infected with KIPyV, 5 (4.5%) were positive for WUPyV, and 3 (2.7%) were infected simultaneously by KIPyV and WUPyV. Neither KIPyV nor WUPyV DNA was detected in samples of healthcare workers. Significant correlations were found in patients co-infected with SARS-CoV-2 and KIPyV (p < 0.05) and between SARS-CoV-2 cycle threshold values and KIPyV, WUPyV and KIPyV and WUPyV concurrently detected (p < 0.05). These results suggest that KIPyV and WUPyV may behave as opportunistic respiratory pathogens. Additional investigations are needed to understand the epidemiology and the prevalence of respiratory polyomavirus in COVID-19 patients and whether KIPyV and WUPyV could potentially drive viral interference or influence disease outcomes by upregulating SARS-CoV-2 replicative potential.en_US
dc.identifier.citationPrezioso C, Moens u, Oliveto, Brazzini, Piacentini F, Frasca, Viscido, Scordio, Guerrizio, Rodio, Pierangeli, d'Ettorre, Turriziani, Antonelli, Scagnolari, Pietropaolo V. KI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients. Microorganisms. 2021;9(1259)en_US
dc.identifier.cristinIDFRIDAID 1914963
dc.identifier.doi10.3390/microorganisms9061259
dc.identifier.issn2076-2607
dc.identifier.urihttps://hdl.handle.net/10037/21730
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.journalMicroorganisms
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleKI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patientsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record